Loading
Every dated change on the records linked to Metastatic pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
OS 13.
Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.
A milestone in how this cancer is treated.
Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.
Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.
Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer
No overall survival benefit from adding devimistat to modified FOLFIRINOX.
Primary overall survival endpoint not met.
A milestone in how this cancer is treated.
Median overall survival 11.
Objective response 21 percent (8 of 38; 95 percent confidence interval 10 to 37); median progression-free survival 4.
OS HR 0.
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
A milestone in how this cancer is treated.
Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic)
Median overall survival 11.
A milestone in how this cancer is treated.